Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
João Pedro Ferreira
ResearcherPublications, citations & collaboration network
João Pedro Ferreira is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 584 works, 22,063 citations, an h-index of 65 and an i10-index of 288.
584
Works
22,063
Citations
65
h-index
288
i10-index
How has João Pedro Ferreira's publication output changed over time?
ScholarIQpublication output · 2020–2025
Output declined83% over the shown period — from 6 works in 2020 to 1 in 2025.
6
3
2
1
2020202120222025
What are the most-cited papers on João Pedro Ferreira?
ScholarIQmost cited works
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Juan Esteban Gómez‐Mesa, Stefan Janssens, James L. Januzzi, José Ramón González‐Juanatey, Béla Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Michele Senni, David Sim, Jindřich Špinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragoş Vinereanu, Jian Zhang, Peter E. Carson, Carolyn S.P. Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad, Milton Packer
New England Journal of Medicine. 20214,718 CitationsOPEN ACCESS
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Faı̈ez Zannad, João Pedro Ferreira, Stuart Pocock, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal, Milton Packer
The Lancet. 20201,397 CitationsOPEN ACCESS
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Adriaan A. Voors, Christiane E. Angermann, John R. Teerlink, Sean P. Collins, Mikhail Kosiborod, Jan Biegus, João Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Jasper Tromp, C. Jan Willem Borleffs, Changsheng Ma, J COMINCOLET, Michael Fu, Stefan Janssens, Róbert Gábor Kiss, Robert J. Mentz, Yasushi Sakata, Henrik Schirmer, Morten Schou, P. Christian Schulze, Lenka Špinarová, Maurizio Volterrani, Jerzy Krzysztof Wranicz, Uwe Zeymer, Shelley Zieroth, Martina Brueckmann, Jon Blatchford, Afshin Salsali, Piotr Ponikowski
Nature Medicine. 2022916 CitationsOPEN ACCESS
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Muthiah Vaduganathan, Brian Claggett, Pardeep S. Jhund, Jonathan W. Cunningham, João Pedro Ferreira, Faı̈ez Zannad, Milton Packer, Gregg C. Fonarow, John J.V. McMurray, Scott D. Solomon
The Lancet. 2020658 CitationsOPEN ACCESS
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart Pocock, Peter E. Carson, Inder S. Anand, Wolfram Doehner, Markus Haass, Michel Komajda, Alan B. Miller, Steen Pehrson, John R. Teerlink, Martina Brueckmann, Waheed Jamal, Cordula Zeller, Sven Schnaidt, Faı̈ez Zannad
Circulation. 2020433 CitationsOPEN ACCESS
Related on ScholarIQ
Inserm
Institution
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Paper
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Paper
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Paper
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Paper
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
Paper